Storia in 4 fonti

Kardigan raises $400M in IPO to back three clinical-stage cardio drugs

Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Kardigan raises $400M in IPO to back three clinical-stage cardio drugs

Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.

originale

Timeline cronologica

mercoledì 17 giugno 2026·biopharmadive.com
Kardigan extends biotech’s streak of big IPOs with $400M haul
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to…
giovedì 18 giugno 2026·morningstar.com
Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan Announces Pricing of Upsized Initial Public Offering

cryptobriefing.com

1 mese fa

Kardigan raises $400M in upsized US IPO, pricing at top of range

Kardigan raised $400 million in its upsized Nasdaq IPO, pricing at $16 per share at the top of its range, signaling renewed biotech investor appetite.

Leggi questa versione → originale

biopharmadive.com1 mese fa

Kardigan extends biotech’s streak of big IPOs with $400M haul

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

Leggi questa versione → originale

morningstar.com1 mese fa

Kardigan Announces Pricing of Upsized Initial Public Offering

Leggi questa versione → originale

giovedì 18 giugno 2026·

endpoints.news

Kardigan raises $400M in IPO to back three clinical-stage cardio drugs

Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.

giovedì 18 giugno 2026·

cryptobriefing.com

Kardigan raises $400M in upsized US IPO, pricing at top of range

Kardigan raised $400 million in its upsized Nasdaq IPO, pricing at $16 per share at the top of its range, signaling renewed biotech investor appetite.